<?xml version="1.0" encoding="UTF-8"?>
<p>Bodies and legs+wings were homogenized separately using a QIAGEN TissueLyser II (Qiagen, Hilden, Germany) and centrifuged at 14,000g for 5 min. Viral RNA was extracted from 140 μl of each homogenate and the saliva expectorates using the Qiagen BioRobot Universal System and QIAamp Virus BioRobot MDx Kit (Qiagen, Clifton Hill, Australia). All samples were analyzed for ZIKV RNA using a real-time TaqMan RT-PCR designed in the nonstructural protein 5 (NS5) gene. Primer and dual-labeled probe sequences (genome nucleotide positions corresponding to ZIKV MR766, GenBank accession number AY632535) were as follows: forward primer (Zika –F-2007) 5’-
 <sup>9845</sup>CCTCAAGGATGGGAGATCCA
 <sup>9864</sup>-3’, reverse primer (Zika-R-2007) 5’-
 <sup>9908</sup> AGCTCGGCCAATCAGTTCAT
 <sup>9889</sup>-3’ and probe (Zika-FAM-2007) 5’FAM-
 <sup>9868</sup> TGGTCCCTTGCCGCCACCA
 <sup>9886</sup> TAMRA-3’. Primer and probe oligonucleotides were synthesized by Sigma-Aldrich (Australia). Separate synthetic primer and probe oligonucleotides were also designed to prepare 
 <italic>in vitro</italic> transcribed RNA positive assay controls. The synthetic assay control sequences incorporated T7 promoter (bold), ZIKV TaqMan primer or probe (italics) and ubiquitin-conjugating enyzyme E2 D2 (UBE2D2) housekeeping gene (underlined) sequences (protocol adapted from Smith et al. [
 <xref rid="pntd.0004959.ref024" ref-type="bibr">24</xref>]). The primer assay control (NS5-Zika-synPri) 5’-AAAA
 <bold>TAATACGACTCACTATA</bold>GGG 
 <italic>CCTCAAGGATGGGAGATCCA</italic>A
 <underline>TGATCTGGCACGGGACCCTCCA</underline>A 
 <italic>ATGAACTGATTGGCCGAGCT</italic>-3’ and probe assay control (NS5-Zika-synPro) 5’-AAAA
 <bold>TAATACGACTCACTATA</bold>GGG
 <underline>TGAAGAGAATCCACAAGGAATTGA</underline>A 
 <italic>TGGTCCCTTGCCGCCACCA</italic>A
 <underline>CAGTGTTCAGCAGGTCCTGTTG</underline>-3’ synthetic assay control oligonucleotides were synthesized by GeneWorks Pty. Ltd. (Adelaide, Australia).
</p>
